Sviluppa il trapianto di microbiota fecale (FMT) per colite ulcerosa, tumori e Parkinson, con supply chain proprietaria.
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Series B Metagen Therapeutics closed its Series B at 3.52 billion yen in total, with a 1.19 billion third close subscribed by CVCs of Aska, Canon MJ, Matsukiyo Cocokara and Medipal. | $22.9M |